Lenalidomide belongs to a novel class of drugs called Immunomodulators which are now being used for the treatment of plasma cell dyscrasias with variable degrees of efficacy and toxicity. Though Second Primary Malignancies (SPM) have been a concern with its use, the benefits of the treatment outweigh the risks. The leukemogenic risk seems to be potentiated especially when combined with alkylating agents and the SPMs documented are predominantly myeloblastic. To date there are no reported cases of new lymphocytic leukemias in AL amyloidosis, regardless of whether undergone treatment or not. We present a case of AL amylodosis who was treated with lenalidomide and subsequently developed acute lymphoblastic leukemia.
Published In/Presented At
Nair, R., Gheith, S., Popescu, D., & Agostino, N. M. (2014). A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide. International Journal Of Clinical And Experimental Pathology, 7(5), 2683-2689.
Hematology | Hemic and Lymphatic Diseases | Medicine and Health Sciences | Oncology | Pathology
Department of Medicine, Hematology-Medical Oncology Division, Department of Pathology and Laboratory Medicine